Baseline Kidney Function, Albuminuria, and Urine Albumin-Creatinine Ratio Reduction with Finerenone, Empagliflozin, or Both: Post Hoc Analyses of CONFIDENCE Trial.

Journal:

Journal of the American Society of Nephrology

Published:

2025-11-07

DOI:

10.1681/asn.0000000928

Affiliations:

15

Authors:

13

Go to article

Institutions	Authors	Share
Bayer, Germany	1.000000	0.08
Velocity Clinical Research, United States of America (USA)	1.000000	0.08
Bayer U.S., United States of America (USA)	1.000000	0.08
Bayer HealthCare, China	1.000000	0.08
Washington University in St. Louis (WUSTL), United States of America (USA)	1.000000	0.08
Brigham and Women's Hospital (BWH), United States of America (USA)	1.000000	0.08
Indiana University (IU), United States of America (USA)	1.000000	0.08
The University of Tokyo (UTokyo), Japan	1.000000	0.08
Duke University, United States of America (USA)	1.000000	0.08
The University of North Carolina at Chapel Hill (UNC), United States of America (USA)	1.000000	0.08
University Medical Center Groningen (UMCG), RUG, Netherlands	1.000000	0.08
KfH-Nierenzentrum, Germany	0.500000	0.04
University of Erlangen-Nuremberg (FAU), Germany	0.500000	0.04
Steno Diabetes Center Copenhagen (SDCC), Denmark	0.500000	0.04
University of Copenhagen (UCPH), Denmark	0.500000	0.04

Interested in Cardiovascular Medicine and Haematology?